Company / SG&A Expense
Outlook Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$29.9M
FY2025
5-year range
$9.4M / $29.9M
FY2021-FY2025
Trend
+219.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense changed +220% YoY in FY2025, a notable deviation from the 5-year average annual change of +43%.
Based on SEC 10-K filings.
$30M in FY2025 with a 5-year CAGR of +26.2%.
Increased from $14M to $30M over the past 6 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +26.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +26.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 219.5% year-over-year.
- Lowest sg&a expense in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $29.9M | +219.5% |
| FY2020 | $9.4M | -34.1% |
| FY2019 | $14.2M | -10.4% |
| FY2018 | $15.9M | -26.3% |
| FY2017 | $21.6M | +67.1% |
| FY2016 | $12.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026